  The inaugural SLAS 2012 in San Diego was a great success for BMG LABTECH, a Diamond Sponsor of this premier automation and screening conference. Most attendees were enthralled with the new Gold-Standard for High-throughput Screening (HTS), the PHERAstar FS, while others were attracted to the new Atmospheric Control Unit (ACU), cell-based assay screening accessory for the Omega series of microplate readers.
|
|
Tutorials
- Automated Platform tailored for HTS in nanoliter volumes- The Ability to Go Smaller
As 1536-well plates were introduced to high throughput screening (HTS), adoption was not immediate. Now instruments with 1536-well capability are a mandatory consideration for most HTS workflows. Will the pattern stay true for screening in 3456-well formats? In this tutorial, BMG LABTECH and Labcyte present a new platform incorporating next generation instrumentation and software for nanoliter-scale HTS. See how this fully automated nanoHTS platform can screen more compounds faster while lowering your average screening costs.
- New HTS Tools for Discovering Low Affinity Inhibitors in Primary and Secondary Screens
Analysis of high-throughput screening data has shown two trends, classic HTS platforms have not delivered the number of expected drug leads as once thought and the more promising leads have lower molecular weights. Since HTS assays are performed at low volumes and low concentrations, are the more marketable lower affinity drug targets being missed with current, less sensitive platforms? In this tutorial learn how lower affinity hits are found in a primary and a secondary high-throughput screen that were missed using current technology. The next generation PHERAstar FS outperforms two competing drug discovery technologies, a charged coupled device (CCD) based microplate reader used for HTS and a flow cytometer used for high content screening (HCS). Being faster and having far superior assay quality parameters (Z prime, delta F% and assay window) in the IP-One HTRF® and fluorescent cell-based assays, the PHERAstar FS represents a new choice for finding low affinity compounds in primary and secondary screening paradigms.
|
|
 |
Posters:
Click on the title to download the posters:
- Next-Generation HTS Instrument Discovers Low Affinity Inhibitors of the Inositol Phosphate (IP)
Signaling Pathway
EJ Dell1, JL Tardieu2, F. Degorce2, Michael Fejtl1
1BMG LABTECH 2Cisbio Bioassay
- Nano High-Throughput Screening (nHTS) Platform – Miniaturization of Cell-based GPCR and Kinase Assays
Authors: E. Dell1, S. Sastry2, D. Bassoni2, J. Barco3, C. Glazer3, H.Lee3 and T. Wehrman2
1BMG LABTECH (North Carolina, US); 2DiscoveRx (Freemont, US); 3Labcyte Inc (Sunnyvale, US)
- Validation of Transcreener® Fluorescent Polarization Assays using BMG LABTECH`s PHERAstar Plus.
Meera Kumar1, Tom Zielinski1, Franka Ganske2 and Edward J. Dell2
BellBrook Labs, Madison, WI, USA1 ; BMG LABTECH, Inc. Cary, NC, USA2
|
